⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 19, 2024PharmacoEconomics - OpenOpen Access

Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

Sergio Cedillo Almudena González‐Domínguez Yoana Ivanova-Markova Rafael López López Sara López‐Tarruella José Alberto Peña Pedrosa

View Full Paper

Ask AI

Bookmark

Share

Abstract

Here we estimate the cost-effectiveness of olaparib in the Spanish National Health Service (SNHS) as adjuvant treatment of early germline mutations in the BRCA1/2 genes (gBRCAm) HER2-negative (HER2neg) breast cancer (BC) with high risk of recurrence.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cedillo et al. (2024) studied this question.

synapsesocial.com/papers/68e5bc37b6db643587554429 https://doi.org/10.1007/s41669-024-00518-2

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer2024
2Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer2024 · 1 citations
3Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trialHuman Clinical Trial · 2026
4Economic evaluation alongside the PAOLA-1 /ENGOT-ov25 trial: cost of ovarian cancer and cost-effectiveness of olaparib plus bevacizumab first-line maintenanceRCT · 2026
5Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina2024